AngioDynamics Offers New, High Flexibility RFA Device for Cancer Tumor Ablation

Share Article

The new StarBurst® XLi-Enhanced Semi-Flex probe from AngioDynamics (NASDAQ: ANGO) is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm ablation of a tumor in a single placement during Computed Tomography-aided procedures.

The new StarBurst® XLi-Enhanced Semi-Flex probe from AngioDynamics (NASDAQ: ANGO) is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm ablation of a tumor in a single placement during Computed Tomography-aided procedures.

"The Semi Flex XLi-Enhanced probe will allow us to reach and treat tumors that were previously untreatable by percutaneous radiofrequency ablation," said Dr. Kevin Hirsch, Interventional Radiologist and Chairman of the Department of Radiology at Banner Good Samaritan Medical Center. "We are very excited for our patients."

The StarBurst series of devices deploy radiofrequency electrode tines - from the end a long wand inserted into the body percutaneously - to raise the temperature of cells above 45-50°C and cause cellular death. Used by surgical oncologists, hepatobiliary surgeons, liver transplant surgeons, laparoscopists and interventional radiologists, these systems offer patients with unresectable liver lesions an effective treatment option with few side effects or complications.

Physicians can now call upon a single device with both the ablation capability of the StarBurst XLi-Enhanced probe, and the flexibility of the Semi-Flex device and its ability to maneuver around a Computed Tomography (CT) gantry. The StarBurst XLi-Enhanced Semi-Flex reduces the time required to perform procedures and can enable patients to resume normal activity within days.

"AngioDynamics' radiofrequency devices have the lowest local tumor recurrence following treatment of all three RFA devices on the US market," said Jan Keltjens, AngioDynamics CEO. "This new tool continues to build on our market leadership."

The scalable design can create ablations from 4-7cm, allowing physicians procedural flexibility. The device also gives dynamic, real-time temperature readouts and needle track ablation. The design provides superior ergonomics and clinician controls. An infusion-based system increases conductivity of the ablation zone, and an integrated tubing set allows for easy set up.

The new device is versatile with both rigid metal and flexible polymer trocar sections. Its ability to bend up to 90 degrees in all directions enables easy gantry entrance for CT systems. It can be used for percutaneous, laparoscopic and intraoperative procedures.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment peripheral vascular disease and cancer. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at http://www.AngioDynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2008. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Courtney Dugan
Visit website